STOCK TITAN

Defence Therapeu Stock Price, News & Analysis

DTCFF OTC

Welcome to our dedicated page for Defence Therapeu news (Ticker: DTCFF), a resource for investors and traders seeking the latest updates and insights on Defence Therapeu stock.

Defence Therapeutics Inc. (DTCFF) is a clinical-stage biopharmaceutical company pioneering next-generation cancer therapies and precision drug delivery systems. This page provides investors and industry stakeholders with timely updates on the company’s clinical trials, strategic partnerships, and technological advancements.

Access the latest press releases and news covering Accum™-enabled therapeutics, including radiopharmaceuticals, antibody-drug conjugates (ADCs), and immune-oncology vaccines. Stay informed about regulatory milestones, licensing agreements, and intellectual property developments that underscore the company’s position in the biotech sector.

Key updates include progress in Phase I trials for AccuTOX®, collaborations with research institutions, and patent grants for novel drug delivery methods. All content is curated to provide a comprehensive view of Defence Therapeutics’ scientific and corporate trajectory.

Bookmark this page for streamlined access to verified updates on DTCFF’s innovations in oncology and infectious disease treatment. Regularly updated to reflect the company’s evolving role in advancing targeted therapies.

Rhea-AI Summary

Defence Therapeutics (OTCQB: DTCFF), a biotechnology company focused on drug delivery technologies, has announced a non-brokered private placement of debenture units. The company aims to raise up to $1.2 million through the offering of units priced at $1,000 each.

Each unit comprises an 8.0% convertible debenture with a two-year maturity and 1,666 common share purchase warrants. The debentures are convertible into common shares at $0.60 per share, while warrants are exercisable at $0.75 per share for two years. Interest payments will be made annually either in shares at the conversion price or in cash at the company's discretion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.86%
Tags
none
-
Rhea-AI Summary

Defence Therapeutics (OTCQB: DTCFF) has announced progress in its cancer therapy programs utilizing its proprietary Accum® technology in both Antibody Drug Conjugates (ADCs) and radiopharmaceuticals. The company's Accum®-based ADCs have shown enhanced efficacy in preclinical cancer models compared to conventional ADCs.

Defence is conducting studies through the Canadian Nuclear Laboratories under the CNRI-H program, focusing on biodistribution, pharmacokinetic profiles, and therapeutic potency. The company operates primarily from its Montreal laboratory while planning U.S. expansion. The target markets show significant potential, with the global ADC market projected to reach $29.9 billion by 2034 (9.23% CAGR) and the radiopharmaceutical market expected to hit $16.87 billion by 2033 (9.9% CAGR).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Defence Therapeutics (DTCFF) has received USPTO Notice of Allowance for patent application 18/351,291 covering next-generation antibody-drug conjugate (ADC) technology. The patent, valid until 2043, includes composition-of-matter claims for therapeutically active ADCs and their use in treating diseases like cancer. The company's Accum-based ADCs have shown enhanced intracellular delivery and cytotoxic activity in preclinical cancer models compared to conventional ADCs. The technology features antibodies conjugated to innovative constructs with bile acid and nuclear localization signal from RPS17. This adds to Defence's existing patent portfolio, which includes granted patents in the US, Japan, Australia, and Israel, marking their eighth U.S. patent overall.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Defence Therapeutics (DTCFF) has announced the opening of its first U.S. laboratory in the Boston-Cambridge biotech hub, specifically at Cambridge Scientific Labs in Watertown. This strategic expansion represents Defence's initial physical presence in the United States and will focus on developing and optimizing its proprietary Accum® technology for antibody-drug conjugates (ADCs). The company plans to use this location as a temporary base while exploring options for a permanent facility in the area. The move positions Defence within one of the world's leading biotech clusters, providing access to top scientific resources and collaboration opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.05%
Tags
none
-
Rhea-AI Summary

Defence Therapeutics (OTCQB: DTCFF) has announced its participation in the BIO International Convention in Boston from June 16-19, 2025. The company's CEO and COO will attend this prestigious event, which attracts over 20,000 industry leaders worldwide. At the convention, Defence will showcase its Accum® technology, designed to enhance antibody-drug conjugates (ADCs) efficacy and improve tumor-killing capabilities.

The BIO International Convention serves as a vital platform for networking, fostering collaborations, and exploring investment opportunities in the biotechnology sector. Defence aims to leverage this event to advance discussions with potential partners and investors, supporting its mission to develop next-generation cancer therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Defence Therapeutics (DTCFF) has announced a collaboration with Canadian Nuclear Laboratories (CNL) to enhance cancer treatments using a combination of Actinium-225 (Ac-225) and Defence's proprietary Accum® technology. The partnership aims to improve the delivery and efficacy of radio-immunoconjugate therapies.

The collaboration will focus on preclinical studies where CNL will evaluate tumor-targeting antibodies modified with Accum® technology to transport Ac-225. The research will assess biodistribution, therapeutic potency, and safety profiles in rodent models. Accum® technology is designed to enhance the escape of Ac-225-antibody complexes from cellular endosomes, potentially improving their nuclear accumulation while reducing required dosage levels and side effects.

CNL will produce and supply Ac-225 from its Th-229/Ac-225 generator at Chalk River Laboratories. This initiative aligns with the growing radiopharmaceutical market, projected to reach USD 16.87 billion by 2033.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Defence Therapeutics (DTCFF) has appointed Dr. Elias Theodorou as Chief Operating Officer, effective April 2025. Dr. Theodorou brings over 25 years of experience in cancer research, stem cell differentiation, and gene delivery to the biopharmaceutical company.

A Yale University Ph.D. graduate and co-founder of Protos Biologics Inc., Dr. Theodorou previously served as Director of Research at WBC Biosciences , where he co-invented methods to enhance immune cells' anticancer properties. Based in the Boston area, he will focus on advancing Defence's Accum® technology and strengthening the company's position in the US biotech market.

As part of his compensation package, Dr. Theodorou has been granted 350,000 stock options, with 100,000 vesting immediately and 250,000 vesting in one year, exercisable at $1.07 per share over ten years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Defence Therapeutics (OTCQB: DTCFF) has completed the second tranche of its non-brokered private placement, raising $3.915 million through a fully subscribed financing totaling $4.2 million. The company offered units at $0.60 per unit, with each unit comprising one common share and one warrant exercisable at $0.75 for 24 months.

The company paid $217,680 in finder's fees and issued 372,000 finder's warrants exercisable at $0.75 per share. PowerOne Capital Markets acted as a finder for part of the offering. Additionally, Defence granted 250,000 stock options to board members at $1.02 per share for ten years and 100,000 options to a consultant for three years.

The proceeds will be used to advance preclinical and clinical programs and for general working capital. All securities are subject to a four-month statutory hold period.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
none
-
Rhea-AI Summary

Defence Therapeutics (DTCFF) has announced its participation in the Biotech Showcase™ conference during the J.P. Morgan Healthcare Conference in San Francisco from January 13-16, 2025. The company's CEO and CSO will meet with industry leaders, potential partners, and investors to showcase their proprietary Accum® technology platform, particularly its applications in improving ADCs and developing targeted radiopharmaceutical therapies.

Additionally, Defence has completed the first tranche of its non-brokered private placement, raising $300,000 through units priced at $0.60 each. Each unit includes one common share and one warrant exercisable at $0.75 per share for 24 months. The company paid $24,000 in finder's fees and issued 40,000 finder's warrants. The proceeds will support preclinical and clinical programs and working capital.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
none
News
Rhea-AI Summary

Defence Therapeutics (DTCFF) has strengthened its patent portfolio with multiple key patent issuances and allowances. The USPTO issued a Notice of Allowance for US patent application 18/318,384, filed in May 2023, covering Accum®-based dimers and multimers. This patent, expected in early 2025, will provide market exclusivity until 2043 for Defence's AccuTOX® and ARM® anti-cancer programs.

The company also secured US patent 12,150,989 on November 26, 2024, extending protection of Accum®-based immunogenicity-enhancing variants to steroid acid-based compounds. Additionally, a Singaporean patent application was recently allowed and is expected to be granted in early 2025.

These developments strengthen Defence's intellectual property position for licensing and strategic partnerships, particularly in improving vaccine potency. The company plans additional national patent filings in Q3 2025 through PCT application PCT/CA2023/051758.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Defence Therapeu (DTCFF)?

The current stock price of Defence Therapeu (DTCFF) is $0.5299 as of August 25, 2025.

What is the market cap of Defence Therapeu (DTCFF)?

The market cap of Defence Therapeu (DTCFF) is approximately 24.4M.
Defence Therapeu

OTC:DTCFF

DTCFF Rankings

DTCFF Stock Data

24.40M
52.80M
3.31%
Biotechnology
Healthcare
Link
Canada
Vancouver